Sales of implants are set to fall sharply as non-urgent procedures are deferred.
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
A new player has entered the liquid biopsy game.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.